Sharemaestro Newsreel

Merck EVP DeLuca sells $5.9m in stock By Investing.com

Richard R. DeLuca, Executive Vice President and President of Merck Animal Health, sold 45,320 shares of Merck & Co., Inc. (NASDAQ:MRK) common stock for approximately $5.9 million between August 10 and August 12, 2026. Following these transactions, DeLuca directly owns 110,167.07 shares. This news …

Modular Medical, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026

Modular Medical, Inc. has released its earnings results for the first quarter ending June 30, 2026. The company reported a net loss of USD 6.49 million, an improvement from USD 6.7 million in the prior year. Basic and diluted loss per share from continuing …

NEOGEN CORP (NEOG) grants CAO stock options and RSUs in new equity awards

NEOGEN CORP's Chief Accounting Officer, John Patrick Moylan, received new equity awards on August 14, 2026. These awards include options to purchase 18,693 shares of common stock at an exercise price of $11.65, expiring in 2036, and 8,584 restricted stock units (RSUs). Both the …

A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $35 to $36

This article provides a brief overview of recent analyst ratings for 4D Molecular Therapeutics (FDMT.US), highlighting that analysts have set price targets ranging from $35 to $36. The information suggests a positive outlook from financial experts regarding the company's stock performance.

AVAH Jumps As Aveanna Healthcare Wins Wave Of Analyst Upgrades

Aveanna Healthcare Holdings Inc. (AVAH) saw its stock rise by 9.11% following strong Q2 2026 results that surpassed analyst estimates for revenue and adjusted EPS, leading to increased guidance for 2026. Major firms like Raymond James, BMO Capital, Deutsche Bank, and UBS raised their …

BMO Capital Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $20

BMO Capital has initiated coverage on MapLight Therapeutics (MPLT.US) with a Buy rating and set a price target of $20. This indicates a positive outlook from the investment firm regarding the company's future stock performance.

Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock

Mittie Doyle, CMO at Avalo Therapeutics (NASDAQ:AVTX), sold 679 shares for $13,580 after exercising stock options under a Rule 10b5-1 trading plan. Following these transactions, she directly holds 51,776 shares and 114,413 stock options. This news follows Avalo's inclusion in the Russell 2000 and …

Alcon (SWX:ALC) Stock Trades At A Discount On Cash Flow But A Premium On Earnings

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Alcon stock presents a clear valuation split right now. The intrinsic value estimate from a Discounted Cash Flow (DCF) approach points to a large upside gap, while …

Gates Capital Management, Inc.'s The Cooper Companies Inc(COO) Holding History

Gates Capital Management, Inc. holds 1.69 million shares of The Cooper Companies Inc (COO), valued at $121.09 million, representing 2.91% of their portfolio. The investment, initiated in Q2 2026 at an average price of $65.47, has resulted in an estimated gain of $18.61 million, …

HTFL Surges As Heartflow Stock Spikes On Strong Q2 Beat

Notable trades: Netflix, Coca-Cola, Pfizer among notable names

Insider transactions were seen across major firms this week, including Netflix (NFLX [https://seekingalpha.com/symbol/NFLX]), Merck (MRK [https://seekingalpha.com/symbol/MRK]), and Pfizer (PFE [https://seekingalpha.com/symbol/PFE]). The following trades took place between August 10 and August 14. * Netflix (NFLX [https://seekingalpha.com/symbol/NFLX]) Chief Financial Officer Spencer Neumann sold 9,248 shares at …

NTLA|Intellia Therapeutics Inc|Price:11.910|Chg%:+0.080

SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript

Eton Pharmaceuticals Soars After Blowout Q2 And Guidance Hike

Eton Pharmaceuticals (NASDAQ: ETON) experienced a significant stock surge of over 45% after reporting blowout Q2 earnings and raising its 2026 revenue guidance. The company's Q2 non-GAAP EPS and revenue significantly beat consensus estimates, driven by strong growth and the successful relaunch of Hemangeol. …

CorMedix Inc (CRMD) Stock News Today

MacroGenics 2026: Revenue $32.83M, EPS $0.31— 10-Q Summary

MacroGenics reported strong Q2 2026 results with revenue of $32.83M and diluted EPS of $0.31, largely driven by a TZIELD milestone payment and increased ZYNYZ royalty income. The company achieved net income of $19.52M, a significant improvement from the prior year's loss, following the …

AKO CAPITAL LLP's Waters Corp(WAT) Holding History

This article details AKO CAPITAL LLP's investment history in Waters Corp (WAT) as of June 30, 2026. AKO CAPITAL LLP holds 203,356 shares valued at $76.27 million, representing 1.78% of their portfolio. The firm has made 8 purchases and 4 sales of WAT shares …

PTC Therapeutics Is Maintained at Overweight by Barclays

Barclays has reiterated its 'Overweight' rating on PTC Therapeutics (PTCT). The analyst firm maintained a price target of $70.00 for the company's stock. This indicates a positive outlook from Barclays regarding PTC Therapeutics' future performance.

AbbVie Defends Its Turf, But Leaves One Big Question Open

AbbVie (ABBV) is performing strongly, with its stock up and sales growth beating expectations, though its EPS guidance was slightly trimmed due to an acquisition. While the company successfully defended its SKYRIZI sales against new competition, analysts are still concerned about its future pipeline …

Will Aurinia’s Reaffirmed 2026 Guidance and Large Buyback Reshape Aurinia Pharmaceuticals' (AUPH) Narrative?

Acumen Pharmaceuticals Inc (ABOS) Stock News Today

Why is Hims & Hers Health stock gaining today?

Teleflex’s Q2 Earnings Call: Our Top 5 Analyst Questions

Teleflex's Q2 Earnings Call: Our Top 5 Analyst Questions Teleflex's second quarter was marked by revenue and non-GAAP earnings per share above Wall Street expectations, yet the operating margin declined significantly year over year. Management attributed the quarter's results primarily to strong execution in …

Nasdaq, S&P 500 Futures Edge Lower Ahead Of Fed Week, AI Earnings Test: Why POET, ATOM, OGN, QCOM, NTLA Are In Focus

Piper Sandler Reaffirms Their Buy Rating on Nektar Therapeutics (NKTR)

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Just Slashed This Year's Revenue Estimates By 22%

Analysts have significantly cut their revenue estimates for Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) for the current year by 22%, now projecting US$83m for 2026, a 38% decline from previous sales. This downgrade reflects a more pessimistic outlook, with the company's revenue decline expected to …

Freenome (FRNM) 10K Form and Latest SEC Filings 2026

This article provides an overview of Freenome's (FRNM) SEC filings, highlighting that the company has submitted over 82 documents since 2024. It details various filing types like 10-K, 10-Q, 8-K, and Form 4, explaining their significance for investors. The most recent filing mentioned is …

What Does Bristol Myers Squibb (BMY) Risk From The Revived $6.7 Billion Lawsuit?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Bristol Myers Squibb (NYSE:BMY) is facing a revived US$6.7b lawsuit after a federal appeals court reinstated claims tied to its Celgene acquisition. Plaintiffs allege the …

Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR)

Citius Oncology, Inc. (NASDAQ:CTOR) is anticipated to reach profitability by 2027, according to analysts, after posting a significant loss in its most recent financial year. The company, which focuses on targeted oncology therapies, is expected to achieve an average annual growth rate of 60% …

Don't Ignore The Insider Selling In Rocket Pharmaceuticals

A Chief Operating Officer at Rocket Pharmaceuticals recently sold US$128k worth of shares, representing 6.8% of their holding. This sale was the largest insider sale in the past year, though it occurred around the current market price, making it less concerning than sales at …

Q1 2026 ICU Medical Inc Earnings Call Transcript

This article provides the edited transcript of ICU Medical Inc.'s Q1 2026 earnings call, which took place on May 7, 2026. The call began with an introduction from an unidentifiable speaker, followed by Thompson from ICR who welcomed participants to discuss the financial results. …

The Bull Case For Alignment Healthcare (ALHC) Could Change Following Its Top Medicare Advantage Pick Recognition

Sutro Biopharma, Inc. (NASDAQ:STRO) Just Reported And Analysts Have Been Lifting Their Price Targets

How Investors Are Reacting To Scholar Rock (SRRK) Dual Fill-Finish Readiness Amid Ongoing FDA Review

NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash

MASS|908 Devices Inc.|Price:10.010|Chg%:-0.100